Mucosis Presents Insights on Development of a Novel Needle-Free Vaccine for RSV Prevention at RSV Vaccines for World

Highlights to include anti­genic and immuno­log­i­cal char­ac­ter­is­tics of company’s unique sta­ble pre­fu­sion F RSV sub­unit

Groningen, the Netherlands, November 19, 2015 – Mucosis B.V., a clin­i­cal stage biotech­nol­o­gy com­pa­ny using a pro­pri­etary tech­nol­o­gy plat­form to devel­op next-gen­er­a­tion nee­dle-free human vac­cines for infec­tious dis­eases, today presents key char­ac­ter­is­tics of its unique pre­fu­sion F anti­gen, the core tech­nol­o­gy behind its lead prod­uct, SynGEM®, an intranasal­ly deliv­ered, nee­dle-free vac­cine for the pre­ven­tion of res­pi­ra­to­ry syn­cy­tial virus (RSV). Data were pre­sent­ed at the RSV Vaccines for World con­fer­ence (RSVVW), tak­ing place at the Salk Institute in La Jolla, California.
SynGEM® uses Mucosis’s pro­pri­etary Mimopath® plat­form to acti­vate mucos­al defences, allow­ing more effec­tive pro­tec­tion against infec­tious dis­eases. RSV is a com­mon infec­tion of the lungs and air­ways, which can lead to seri­ous dis­eases such as upper and low­er res­pi­ra­to­ry tract ill­ness and pneu­mo­nia, par­tic­u­lar­ly in infants. Currently there are no vac­cines avail­able against RSV, which is esti­mat­ed to cause 3.4 mil­lion hos­pi­tal­iza­tions and at least 66,000 deaths world­wide each year.
Kees Leenhouts, Ph.D., Chief Scientific Officer at Mucosis, will be pre­sent­ing data on the devel­op­ment of Mucosis’ pre­fu­sion F-type RSV sub­unit vac­cines. Its unique sta­ble form allows it to be used in SynGEM to elic­it pow­er­ful neu­tral­iz­ing anti­bod­ies. Using the anti­gen in a mucos­al vac­cine for­mu­la­tion leads to an immune response both local­ly in the air­ways, where the pathogens enter, as well as sys­tem­i­cal­ly, to pro­vide a more effec­tive defence against RSV.
“The pre­fu­sion F anti­gen is recog­nised as a key area of research in devel­op­ing an effec­tive vac­cine for RSV, due to its abil­i­ty to induce high­ly potent anti­bod­ies against the RSV pathogen,” Dr. Leenhouts com­ment­ed. “Developing an F-type RSV sub­unit vac­cine is chal­leng­ing as the nat­ur­al pre­fu­sion form of the anti­gen is inher­ent­ly unsta­ble. Mucosis has over­come this chal­lenge with SynGEM®, which will be enter­ing human proof-of-con­cept stud­ies in 2016. We are excit­ed to present data on the anti­genic and immuno­log­i­cal char­ac­ter­is­tics of our unique form of the anti­gen at RSV Vaccines for the World 2016.”
This is the sec­ond RSVVW meet­ing, com­pris­ing of keynote pre­sen­ta­tions and spe­cial ses­sions with the goal of bring­ing togeth­er RSV researchers and oth­er inter­est­ed par­ties and researchers to hear updates on progress towards the suc­cess­ful imple­men­ta­tion of vaccines/vaccine strate­gies against the RSV pathogen.
Dr. Leenhouts’ dis­cus­sion, “The devel­op­ment of a pre­fu­sion F-type RSV sub­unit vac­cine,” will take place today, from 12.45-13.00 pm dur­ing Session 5.

Leave a Reply

Your email address will not be published. Required fields are marked *